[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,074,736
  • Shares Outstanding, K 144,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -766,630 K
  • EBIT $ -1,089 M
  • EBITDA $ -1,078 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 47.90% (-7.30%)
  • Historical Volatility 47.24%
  • IV Percentile 5%
  • IV Rank 8.99%
  • IV High 90.62% on 11/04/25
  • IV Low 43.68% on 06/15/26
  • Expected Move (DTE 15) 1.49 (2.54%)
  • Put/Call Vol Ratio 0.84
  • Today's Volume 136
  • Volume Avg (30-Day) 235
  • Put/Call OI Ratio 2.82
  • Today's Open Interest 92,007
  • Open Int (30-Day) 92,274
  • Expected Range 57.09 to 60.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-2.20
  • Number of Estimates 1
  • High Estimate $-2.20
  • Low Estimate $-2.20
  • Prior Year $-1.56
  • Growth Rate Est. (year over year) -41.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.47 +12.24%
on 07/29/26
61.77 -4.66%
on 07/07/26
+1.93 (+3.39%)
since 07/06/26
3-Month
45.30 +30.00%
on 06/11/26
61.77 -4.66%
on 07/07/26
+1.79 (+3.13%)
since 05/06/26
52-Week
29.08 +102.51%
on 08/07/25
65.00 -9.40%
on 02/25/26
+25.89 (+78.45%)
since 08/06/25

Most Recent Stories

More News
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline...

PCVX : 58.89 (+5.31%)
Vaxcyte's Pipeline Timing Assumptions Haven't Been This Visible in Years

Barchart Research What to Expect from PCVX Earnings PCVX Generated August 4, 2026 Current Price $54.69 EPS Estimate $$-1.47 Consensus Rating Moderate Buy Average Move 5.17% Vaxcyte's Pipeline Timing Assumptions...

PCVX : 58.89 (+5.31%)
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one...

PCVX : 58.89 (+5.31%)
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation...

PCVX : 58.89 (+5.31%)
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and...

PCVX : 58.89 (+5.31%)
Vaxcyte Approaches Its First Earnings Call Since Analysts Stopped Raising Targets

Barchart Research What to Expect from PCVX Earnings PCVX Generated May 5, 2026 Current Price $55.69 EPS Estimate $$-1.86 Consensus Rating Strong Buy Average Move 4.17% Vaxcyte Approaches Its First Earnings...

PCVX : 58.89 (+5.31%)
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 58.89 (+5.31%)
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive...

PCVX : 58.89 (+5.31%)
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from...

PCVX : 58.89 (+5.31%)
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 58.89 (+5.31%)
STRO : 24.15 (-3.78%)
LZAGY : 69.5800 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 58.61
2nd Resistance Point 57.68
1st Resistance Point 56.80
Last Price 58.89
1st Support Level 54.99
2nd Support Level 54.06
3rd Support Level 53.18

See More

52-Week High 65.00
Last Price 58.89
Fibonacci 61.8% 51.28
Fibonacci 50% 47.04
Fibonacci 38.2% 42.80
52-Week Low 29.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.